# A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

> **NCT02511132** · PHASE2 · COMPLETED · sponsor: **Gradalis, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Ewing's Sarcoma

## Interventions

- **BIOLOGICAL:** Vigil
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02511132
- **Lead sponsor:** Gradalis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2018-11-12
- **Final completion:** 2020-12-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511132, "A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02511132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*